Tesamorelin is a synthetic 44-amino-acid analog of growth hormone-releasing hormone (GHRH) that has been chemically modified to resist enzymatic degradation. The molecule features a trans-3-hexenoyl group attached to the N-terminal tyrosine residue, which: - Dramatically extends half-life compared to native GHRH - Improves resistance to dipeptidyl peptidase-4 (DPP4) - Maintains GHRH receptor binding affinity - Binds to GHRH receptors in the pituitary gland - Stimulates physiological (pulsatile) GH release - Increases IGF-1 production downstream - Preserves natural feedback mechanisms Studies have examined Tesamorelin in: - Lipodystrophy models (visceral fat reduction) - Metabolic syndrome research - Growth hormone axis investigation - Body composition studies - Visceral adipose tissue: Significant reduction observed - Metabolic parameters: Improved triglycerides and cholesterol ratios - Glucose tolerance: No adverse effects in studies - Muscle quality: Increased density and
Tesamorelin: GHRH Analog Research Guide
Understanding Tesamorelin, the modified growth hormone-releasing hormone analog with enhanced stability.